Targeting cancer with peptide aptamers.

Abstract

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.

• Authors: Renaud Seigneuric, Jessica Gobbo, Pierre Colas, Carmen Garrido
• Journal: Oncotarget (Oncotarget) Vol. 2 Issue 7 Pg. 557-61 (Jul 2011) ISSN: 1949-2553 [Electronic] United States
• PMID: 21709317 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Aptamers, Peptide
• Heat-Shock Proteins
• Recombinant Fusion Proteins

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Antineoplastic Protocols
• Aptamers, Peptide (chemistry, genetics, therapeutic use)
• Clinical Trials as Topic
• Heat-Shock Proteins (metabolism)
• Humans
• Molecular Targeted Therapy
• Nanotechnology
• Neoplasms (drug therapy)
• Recombinant Fusion Proteins (therapeutic use)